Sell News & Analysis
2 articles
Market Mood

Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Trial
Sellas Life Sciences reported that its experimental vaccine for acute myeloid leukemia (AML) achieved a 9-month survival benefit in a late-stage clinical trial. The vaccine reduced the risk of death in people with blood cancer, marking a significant development in cancer immunotherapy. This improved survival is a key milestone supporting the vaccine's effectiveness. The trial results come amid a notable year for breakthroughs in cancer drugs. Sellas' vaccine directly addresses AML, a serious and often deadly form of leukemia. Multiple reputable sources, including Memorial Sloan Kettering Cancer Center and Reuters, confirmed the survival improvement demonstrated by the vaccine in the clinical setting. This advancement could influence cancer treatment approaches and investor interest in oncology biotechs. The 9-month survival extension is concrete evidence of clinical benefit, which could affect future approvals and commercial potential for Sellas. For investors, the improved survival rate is a key factor that might impact the company's prospects and stock performance.
Read More: Sellas Leukemia Vaccine Shows 9-Month Survival Benefit in Trial
Orkla (ORK) Stock Downgraded to Sell Due to Margin Pressure
UBS has downgraded the stock rating of Orkla (ORK) to 'Sell' due to concerns over margin pressure. This shift reflects expectations of decreased profitability, which poses potential risks for investors. The downgrade might influence market sentiment towards Orkla, as analysts assess the company's ability to maintain its margins amid operational challenges. Trading volumes for Orkla are anticipated to fluctuate as investors react to this downgrade and reevaluate their positions in the stock.
Read More: Orkla (ORK) Stock Downgraded to Sell Due to Margin Pressure